


Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection

Authors: Carl-Christian A. Jackson, MD, Jason Newland, MD, MEd, Nataliia Dementieva, MD, Julia Lonchar, MSc, Feng-Hsiu Su, MPH, MBA, Jennifer A. Huntington, PharmD, Mekki Bensaci, PhD, Myra W. Popejoy, PharmD, Matthew G. Johnson, MD, Carisa De Anda, PharmD, Elizabeth G. Rhee, MD, Christopher J. Bruno, MD

Supplemental Digital Content 2

Study Disposition of All Randomized Participants



CE, clinically evaluable; C/T, ceftolozane/tazobactam; EOT, end of treatment; MEM, meropenem; MITT, modified intent-to-treat; mMITT, microbiologic modified intent-to-treat; TOC, test of cure; MTZ, metronidazole.

^aReasons for exclusion were not mutually exclusive.